US-based Penumbra has completed enrolment for the THUNDER Investigational Device Exemption study of its advanced thrombectomy ...

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER ...

Wells Fargo notes that Clinicaltrials.gov lists Penumbra’s THUNDER trial as having reduced the total enrollment number to 216 from 275 as of October 16, so when Penumbra announc ...

Neurons in the ischemic penumbra, referred to as "ischemic neurons", are relatively viable. Microglia can transform into an ...

Needham analyst Michael Matson has maintained their neutral stance on PEN stock, giving a Hold rating on October 21. Michael Matson has given ...

Penumbra, Inc. announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. TH ...

2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic ...